Gout & Mortality

A small increase in all-cause mortality was seen with dose escalation, but only 10% of patients exceeded 300 mg allopurinol daily.

mdedge.com

medpagetoday.com

Contrary to expectation in this 10-year observational study, all-cause, cardiovascular and cancer mortality increased slightly (about 8%) with Allopurinol dose escalation, especially in the first 2 years; albeit the increase was not statistically significant.
But less than a third of the dose-escalators achieved serum uric acid target of <6 mg%.  Among these, there was a 7% reduction in cardiovascular mortality compared to case-matched non-escalators.


CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in…
rheumnow.com

Without a placebo arm, is Allopurinol better, or Febuxostat worse, for all-cause (mainly cardiac) mortality?

Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert

onlinelibrary.wiley.com

Public Citizen Pressures FDA to Pull Febuxostat

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda’s…
rheumnow.com

tctmd.com

Effects of allopurinol versus febuxostat on cardiovascular risk in korean patients with gout: a nation-wide cohort study

ard.bmj.com

“In this large Korean population-based cohort study, CV risks appear to be numerically, but not statistically significantly, elevated among allopurinol initiators compared to febuxostat initiators.”

Gout drug reduces adverse events in patients with hyperuricaemia
medicalxpress.com

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED)

FREED from CARES!

By Walter Alexander…
dgnews.docguide.com